

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2018/2019 influenza season**

as of July 16, 2019

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	5 <sup>a</sup> (1.5%)	17 <sup>b</sup> (0.8%)	17 <sup>b</sup> (0.8%)	0	0	188 (100%)	32 <sup>c</sup> (9.4%)	0	0	0	0	155 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	325	2,073	2,073	316	316	188	341	304	304	304	304	155	38	88	88	88	88
<b>Number of viruses reported</b>	2,949						4,533						497				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patients without treatment 0

<sup>b</sup> Patients without treatment 4

<sup>c</sup> Patients without treatment 4